Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Premaitha | LSE:NIPT | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.10 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 9.00 | 9.20 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 9.10 | GBX |
Premaitha (NIPT) Share Charts1 Year Premaitha Chart |
|
1 Month Premaitha Chart |
Intraday Premaitha Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/11/2018 | 14:51 | Premaitha Health- non invasive prenatal test | 6,468 |
| 11/10/2018 | 09:42 | Michaelmouse school of investing and fraud | 20 |
| 15/2/2017 | 19:27 | Michaelmouse school of investing and fraud | - |
| 26/7/2016 | 05:39 | Premaitha Health (NIPT) report recommends NHS implementation should go ahead | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 12/10/2018 19:22 by michaelmouse LOL.I'll think you'll find my posts were about NIPT until my stalker turned up. I'll leave you with these questions. How much money will they need in the next fund raise? and at what share price? Dilution will be immense making the market cap even more ludicrous. Of course they might not be able to raise the funds, in which case, as it says in the final report, NIPT will go bust. Good luck though. |
Posted at 12/10/2018 06:25 by captain_kurt The current share price is more than 20% below the placing price which itself was 19% below the share price price at that time (which already had a run on it from 15p).Seems a bit overdone imo. Given where the company was when we were previously at this territory (even correcting for the 6% minor share dilution) the share price is too negative. Since then the company has resolved a multi-million dollar litigation to its strategic benefit against a billion dollar company. It has also increased it product range and added £1m to sales. With over 80K sales volumes expected iro this year we should expect Premaitha to have close to 10% of a potentially billion dollar company where strategic interest towards TO has been already shown via warrants at 24p. |
Posted at 10/10/2018 21:54 by ngen yap Been in the stock market for 20 years and share price movements still baffle me! How is it that such low volumes over the last 3 days alone can cause such dramatic falls in the SP?? Even more intriguing is that we only just got an oversubsribed placing off at 10p. Perhaps we fall back to 10p +/- 0.5p but not this! That's why I try to work on the basis of company fundamentals and mid-to-long term targets.I can see Premaitha are busy recruiting different new roles - always a good sign of growth in a company. Been digesting the settlement news, final results, trading update, placing and most recently new service deal for oncology research. What an amazing string of strong and positive developments. Whatever the truth is regarding the placing, with reference to TW's theories of which I only half believe, we are now below the placing price of 10p. So, private investors who may have felt shafted without being afforded a chance to participate in the placing (including TW) can get in at a discount to that! What is very much overlooked is that the founder owner of Yourgene injected £700k further of his own money, to maintain shareholding at 17%+ - this is a very strong signal. We are doing well. We have eliminated the biggest risk / uncertainty in the business - the Illumina litigation. We are now free to operate globally, and in bed with the two largest NGS provider. We are expanding geographically, and continue to. We are expanding our product offering and most recently into new exciting oncology sector. We have a strong management team with significant options at 10p as incentive. The business is simple. Get as many clinics / labs / bases in as many country as we can using our highly competitive product and with the two largest NGS provider (tick). Expand service offerings in the product offerings - Sage, workflow etc (tick). Increase awareness of NIPT (in progress). Expand into new areas eg oncology (tick). Find more efficiencies to deliver better margins (tick). Once foundations set (point 1), growth can be exponential with points 2, 3 and 4. We are very much underway. Note the eye on Americas - for those who haven't, do read their full glossy FY report in Premaitha website. We recorded 34k volume sales in H1 FY18/19. I expect this to be 80k+ by end FY. I foresee FY18/19 revenue to be circa £9.5-£10 Like Adam Reynolds and new CEO, Lynn, I have not been more confident of Premaitha since I invested. See this dip as an opporunity to join those who got in at 10p with a view of 20p soon. My target exit remains at 30-40p! No advice intended. Good luck all. |
Posted at 29/9/2018 17:08 by mhin2 5th June 2018"Premaitha, through its Yourgene subsidiary (“Yourgene&rdq Just hope that the Indian market takes to the test- the NHS use will be a tremendous help. |
Posted at 19/9/2018 06:56 by multibagger Posted for future reference:Share price close on 18 Sep 2018 : Mid-price about 12.7p Premaitha Health PLC 19 September 2018 Legal Settlement and Licence Agreement with Illumina Manchester, UK - 19 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce that the Group has entered into a legal settlement and a licence and supply partnership agreement with Illumina Inc. ("Illumina") (the "Agreements"), resolving the current non-invasive prenatal testing ("NIPT") patent infringement litigation. Key Terms of the Agreements -- Premaitha has taken a licence under Illumina's patent pool for NIPT and is now free to operate in countries where Illumina holds rights to relevant granted patents, including the countries of the European Patent Convention and selected other territories -- Premaitha will develop an IONA(R) test that runs on Illumina sequencing technology, to be launched in early 2020; and within nine months of signing the Agreements has committed to submitting documentation to a notified body for obtaining CE-IVD certification in Europe for the Illumina-compatible IONA(R) test -- Premaitha will work with its customers in the licensed territories to migrate to the IONA(R) test based on Illumina sequencing technology -- Premaitha will make a series of payments in full and final settlement of all ongoing UK litigation. The Directors estimate that these payments will be no more than GBP1m -- Once launched, Premaitha will pay Illumina a royalty per sample tested using the IONA(R) test based on Illumina sequencing technology Lyn Rees, Chief Executive Officer of Premaitha, commented: "These Agreements mark the end of a three and a half year intellectual property dispute and the beginning of a new era whereby the Group, working with Illumina, has the ability to provide NIPT to meet rapidly growing global demand. "Our partnership with Illumina will allow us to move forward and to enter new markets with significant commercial potential. This opens up a much larger addressable market to Premaitha and establishes a new and advanced technological partnership for the IONA(R) test for NIPT. "Notwithstanding the challenges of the past several years, these Agreements represent a significant milestone for the Group, expanding our market potential in partnership with Illumina. Premaitha now has the ability to deliver high quality, customer-service-foc |
Posted at 19/9/2018 06:52 by multibagger Hi Ngen Yap - I seem to recall you from the good old VIY days. Commiserations on your loss, but hopefully it will work out fine for you and others in NIPT.The issue as I see it is that Illumina is forcing all existing customers to be moved across to their equipment and platform. NIPT will have to convince customers to move to Illumina platform and many won't given the cost - so effectively Illumina gain at the cost of NIPT. NIPT will have to go through all the regulatory hassle and can't do anything meaningful till 2020. So Illumina have won hands down. NIPT have just been allowed to exist - this is the price. In the grand scheme of Illumina - NIPT revenues will not even count for a rounding error, but NIPT have been shafted sadly. This is a brutal example of the financial and resulting legal power of companies like Illumina. Sometimes a contrarian viewpoint can help bring aspects into the public domain. Whether I am right or wrong, does not matter to me personally as I am not invested. But I will learn from my "reading" and that will help in the longer term. I wish you all well guys and no hard feelings. Good luck :) |
Posted at 17/9/2018 07:35 by multibagger Interesting upward movement in share price - speculation that Illumina legal wrangle is about to be settled. I am not sure that the likes of Illumina settle in a manner that would help the competition ?More likely that NIPT management will be putting out a "we are unaware of a reason for the current share price movement" if this share price rise carries on. Good luck all :) |
Posted at 05/8/2018 10:05 by scotty1 Snap,I am also in both and although out of the two I personally believe opti as the potential to bag multiple times over the next few years whereas I also believe someone as been accumulating in NIPT over the last few weeks and short term it as the potential to double pretty quick from here as has OPTI,of course a settlement with illumina would see the share price a lot more than that.l also understand that trading at NIPT is strong which will help move the share price higher 😉 |
Posted at 15/5/2018 06:22 by humphries1 15 May 2018Premaitha Health plc ("Premaitha", the "Company" or the "Group") Year-end Trading Update and GBP2.5m Fundraising Revenues doubled in the year ended 31 March 2018 & An additional GBP2.5m funds raised Manchester, UK - 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, provides a trading update for its financial year ended 31 March 2018; announces completion of a share subscription for GBP2.5m cash at a price of 4.5 pence per share; and announces the issue of shares to satisfy GBP0.5m liabilities at a price of 4.5 pence per share. Highlights -- Unaudited Revenues in the year ended 31 March 2018 increased by 100% to GBP6.2m (2017: GBP3.1m), with the majority of growth from outside of Europe -- Test volumes for non-invasive prenatal testing ("NIPT") more than doubled to over 50,000 (2017: 24,500) -- Operating costs effectively managed to achieve a breakeven EBITDA run-rate in NIPT -- Litigation pressures crystallised in the UK during the period. All costs have now been settled pending appeal and the Company is actively engaged in reducing its exposure going forward -- Revenue diversification underway, with progress made in extending the product range, leveraging underlying technologies and developing collaboration partnerships Post Period-end -- Geographic footprint (already in 20 countries) continues to grow strongly, most recently with new contracts in India and Kenya -- Raised GBP2.5m cash by way of share subscription to fund future international growth - of which approximately GBP950,000 invested by directors of the Company -- GBP0.5m in liabilities settled by the issue of new shares -- 'Yourgene Health' brand is being introduced outside of Europe to reflect the broadening of technology offerings beyond NIPT -- Dr William Denman, Chief Medical Officer, has stepped down as a director of the Company Trading Update Unaudited Revenues increased by 100% to GBP6.2m (2017: GBP3.1m) in the first full trading year of the newly enlarged Premaitha group, following the acquisition of Yourgene Bioscience ("Yourgene") in March 2017. On a like-for-like basis, revenues increased 35% versus pro forma 2017 revenues. -- International revenues increased to GBP3.8m (2017: GBP0.9m), reflecting the Group's increased focus on territories including Asia, the Middle East and Africa, where there is high population growth, lower IP risk and a general receptiveness to new medical technologies -- UK revenues remained constant at GBP1.3m (2017: GBP1.2m), with gradual adoption of NIPT within the NHS focused on high risk contingent screening -- Other European revenues were GBP1.1m (2017: GBP1.0m), from a significantly broader network of customers than in the prior year Operating costs have been tightly controlled throughout the period with a number of structural changes implemented to reduce central overheads and UK operating costs by over 20%. The Group has entered the current financial year at an operating breakeven run-rate in its NIPT activities, whilst investment continues in business and product development activities. Commercial momentum has been maintained since the period-end, further demonstrated today with Premaitha's first customer secured in Kenya and further penetration into the Indian market with the Group securing an agreement with a highly reputable laboratory group. Fundraising The Company has issued 55,527,784 new ordinary shares with a number of investors and directors at a price of 4.5 pence per share, raising GBP2.5m before costs. This will be used to fund continued international expansion of Premaitha's sales channels, further product development in NIPT and other clinical applications, and adaptation of the current products to provide a range of general purpose development tools for potential partners in other areas of clinical genetics. In addition, 10,097,460 shares have been issued in lieu of GBP0.5m of amounts owed principally to directors, further details of which are set out below. Director Dealings Certain directors of the Company have participated in the fundraising by subscribing for new ordinary shares in the form of cash and also by accepting new ordinary shares in lieu of outstanding liabilities owed by the Company. Director participations are as shown in the table below: Name Shares New shares New shares Total % of held before purchased issued new shareholding newly transaction for cash in lieu enlarged of existing share liabilities capital --------------- ------------- ----------- ------------- ------------------ ---------- Dr Bill Chang 45,252,469 15,527,778 611,111 61,391,358 15.9% --------------- ------------- ----------- ------------- ------------------ ---------- Peter Collins 3,522,727 222,222 1,523,362 5,268,311 1.4% --------------- ------------- ----------- ------------- ------------------ ---------- Dr Stephen Little 2,772,727 1,111,111 1,444,445 5,328,283 1.4% --------------- ------------- ----------- ------------- ------------------ ---------- Nick Mustoe 3,909,091 3,333,334 944,444 8,186,869 2.1% --------------- ------------- ----------- ------------- ------------------ ---------- Adam Reynolds 3,681,137 555,556 462,963 4,699,656 1.2% --------------- ------------- ----------- ------------- ------------------ ---------- Alan Chang 3,802,729 0 555,556 4,358,285 1.1% --------------- ------------- ----------- ------------- ------------------ ---------- Issued Share Capital Application has been made to the London Stock Exchange for the 65,625,244 new ordinary shares to be admitted to trading on AIM, which is expected to occur on or around 18 May 2018. The new ordinary shares will rank pari passu with existing ordinary shares. Following the admission of shares noted above, the Company will have 386,843,523 ordinary shares in issue. Directorate Change As the Company grows, it is also reorganising Executive roles for greater clarity between execution and strategic responsibilities. Dr William Denman, a founder member of Premaitha, has decided to take this opportunity to step down as a director and consultant to the Company with immediate effect. In consideration for liabilities owed to Dr Denman as at the date of his departure, the Company has issued him 3,755,579 new ordinary shares issued as fully paid. Dr Denman held options over 2,654,989 ordinary shares which lapse upon his departure. Related Party Transactions The participation of Dr Bill Chang, Alan Chang, Dr Stephen Little, Adam Reynolds, Nick Mustoe and Peter Collins in the placing, as well as the issue of shares to Dr William Denman set out above, are related party transactions (the "Transactions"). Consequently, pursuant to AIM Rule 13, Barry Hextall, a director of the Company who is independent of the Transactions, having consulted with the Company's nominated adviser, believes the terms of the Transactions are fair and reasonable insofar as shareholders are concerned. UK NIPT Litigation Update Premaitha has now settled all of the costs provisionally awarded against it by the UK courts in the January 2018 hearing, concerning the UK NIPT patent trial held in July 2017. These costs amounted to GBP2.0m and were paid from the secured loan facility announced on 22 January 2018. At the January 2018 hearing, the Company was granted leave to appeal, which is anticipated to take place in Q1 2019. The Company has also established arrangements for a 10% royalty on UK sales to be paid into escrow during the appeal cycle as ordered by the court at the same January 2018 hearing. The first payment of approximately GBP30,000 has now been made and the royalty is expected to run at approximately that level per quarter until the appeal is heard. Premaitha is now working with new legal advisers to implement a strategy that will minimise the ongoing cost outlay in the UK, whilst achieving the best outcome for the Group as a whole given its international focus. In parallel, the Company is engaged in potential settlement discussions with Illumina and is also adapting its product development roadmap in light of the UK Court's first instance interpretations of the NIPT patents in question. Branding The Group is introducing 'Yourgene Health' as its new corporate branding outside of Europe, reflecting the Company's increasing geographic scope and expansion of its product range into other areas of clinical genetics. The Group will continue to trade as Premaitha Health in Europe, and as Yourgene Bioscience in Taiwan, but will adopt the new brand - Yourgene Health - in all other territories. Dr Stephen Little, CEO of Premaitha Health, commented: "Our first full year as the enlarged Premaitha group has been one of excellent commercial progress following the effective integration of the acquired Yourgene business. To have doubled revenues, with the majority of growth coming from outside of Europe, demonstrates the success of Premaitha's commercial strategy. "I would like to take this opportunity to thank Dr Denman for his significant contribution to the Company from its very earliest days and we wish him every success in his other business interests. Since founding Premaitha, we, and more recently with our Yourgene colleagues, have brought together clinical genetics capabilities in assay development, bioinformatics and IVD commercialisation to create an internationally competitive diagnostics company. "We are now delivering NIPT services to patients in over 20 countries, and have a strong pipeline both in broadening our services with existing customers, as well as in securing new partners. Whilst there are IP challenges associated with operating in the NIPT space, there are also significant opportunities, and we will continue to develop our offering in this high-growth segment. "We remain keenly focused on leveraging our existing technological capabilities to develop additional products and services across the clinical genetics market, thereby creating additional revenue streams for the Group. We believe the combination of the Yourgene and Premaitha teams puts us in a unique position to successfully deliver clinical genetics capabilities in assay development, bioinformatics and IVD commercialisation. We appreciate the support shown by investors in the fundraising and we look to the future with confidence." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. For more information, please contact: Premaitha Health PLC Tel: +44 (0)161 Dr Stephen Little, Chief Executive 667 1053 Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing investors@premaitha. Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 Liam Murray / James Caithie 7213 0880 finnCap (Broker) Tel: +44 (0)20 Adrian Hargrave / Scott Mathieson 7220 0500 (Corporate Finance) Andrew Burdis / Abigail Wayne (Corporate Broking) Vigo Communications Tel: +44 (0)20 Ben Simons / Fiona Henson / Antonia 7830 9700 Pollock premaitha@vigocomms. About Premaitha Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's current primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market - although the Group intends to expand its product range into other areas of clinical genetics. Premaitha's first product, the IONA(R) test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA(R) test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA(R) test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage. In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening solution that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA(R) test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond. From May 2018, the Group will trade as Yourgene Health outside of Europe (but remaining as Yourgene Bioscience in Taiwan) reflecting the increased scope of the business in other areas of clinical genetics further to reproductive health; but will maintain the Premaitha Health brand within Europe. Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth. This information set out below is provided in accordance with Article 19(3) of EU Regulation 596/2014. 1. Details of PDMR / person closely associated --- -------------------- a) Name (i) Dr Bill Chang (ii) Peter Collins (iii) Dr Stephen Collins (iv) Nick Mustoe (v) Adam Reynolds (vi) Alan Chang --- -------------------- 2. Reason for the notification --- -------------------- a) Position / status (i) Chief Scientific Officer (ii) Chief Business Officer (iii) Chief Executive Officer (iv) Non-Executive Director (v) Non-Executive Chairman (vi) Non-Executive Director --- -------------------- b) Initial notification /amendment Initial notification --- -------------------- 3. Details of the issuer --- -------------------- a) Name Premaitha Health plc --- -------------------- b) LEI 213800UUIT8BZE7QEH33 --- -------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- -------------------- a) Description of the financial instrument Ordinary Shares of 0.1p each --- -------------------- b) Identification code of the Financial Instrument ISIN for Premaitha Health plc: GB00BN31ZD89 --- -------------------- c) Nature of the transaction Subscription and new shares issued in lieu of existing liabilities --- -------------------- d) Price(s) and volume(s) Price Volume (i) 4.5p (i) 16,138,889 (ii) 4.5p (ii) 1,745,584 (iii) 4.5p (iii) 2,555,556 (iv) 4.5p (iv) 4,277,778 (v) 4.5p (v) 1,018,519 (vi) 4.5p (vi) 555,556 --- -------------------- f) Date of the transaction 18 May 2018 --- -------------------- g) Place of the transaction XLON --- -------------------- |
Posted at 15/5/2018 06:22 by humphries1 15 May 2018Premaitha Health plc ("Premaitha" or the "Company") Premaitha expands footprint with new laboratories in Kenya and India Manchester, UK - 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing ("NIPT"), announces that it has further extended its customer base, adding two new laboratory hubs, one in Kenya - a new territory for Premaitha - and the other in India. In Kenya, the Group has signed an agreement with Massive Genomics, part of the Nairobi IVF Centre in Kenya, to establish a dedicated NIPT centre. The Nairobi IVF Centre intends to offer NIPT to each of the c. 5,000 women who visit the centre each year. The laboratory will be set up directly by Premaitha, with Massive Genomics, and will be operational by September 2018. There is a high level of understanding and awareness of the benefits of NIPT in Kenya, but currently all NIPT samples are sent out of the country for analysis, resulting in a delay between the sample being taken and the results being received. The Massive Genomics laboratory will be the first to offer NIPT in-country. In addition, as the only laboratory in the region capable of processing NIPT in-house, there is potential for Massive Genomics to broaden its scope into other east African countries with which it has relations, such as Uganda, Botswana and Tanzania. The Group has also signed an agreement with a leading laboratory group in India to set up an NIPT-focused laboratory in Gujarat, a region in the northwest which, once installed, is expected to act as a hub for a network of laboratories across India. NIPT is in the early phase of development in India but, with over 26 million births per annum, and increasing awareness of the benefits of NIPT, Premaitha expects India will be a key growth market as the Company continues to grow its presence in the region. Premaitha's IONA(R) test estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The test is performed on a maternal blood sample, containing traces of fetal DNA, which is then analysed using next generation DNA sequencing technology. The test is highly accurate and significantly reduces the number of women who are unnecessarily subjected to risky, invasive follow up procedures to diagnose Down's syndrome and other genetic conditions. Dr Stephen Little, CEO of Premaitha Health, commented: "I am pleased to report further progress in growing our footprint in key growth markets. Kenya is another international territory which we believe will, when fully established, contribute a growing number of recurring test sales. Massive Genomics is well placed to draw demand for NIPT from both within Kenya and the surrounding region. We also continue to build upon our presence in India, where we believe there are substantial opportunities underpinned by continued growth in demand for NIPT, driven by both increasing awareness and accessibility." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
